Human breast tumors are infiltrated by memory CD4 þ T cells along with increased numbers of regulatory T 
Introduction
In several cancers, tumor growth and dissemination are associated with perversion of the immune system (1). We and others have shown that primary breast tumor-associated T cells (TA-T), are highly enriched in CD25 hi CD127 low FoxP3 hi CD4 þ regulatory T cells (Treg; ref. 2) and that high infiltration of TA-Treg in breast tumor, and more particularly within lymphoid aggregates surrounding tumor correlates with poor prognosis (2) . In the past decade, several studies highlighted the negative impact of TA-Treg on Th1 and cytotoxic T lymphocytes mediated antitumor immunity (3) . Therapeutic targeting of Treg is clearly beneficial in mice as shown in multiple models based on anti-CD25 depletion (for review refs. 3, 4) or FoxP3 deletion (3, 5) . A similar approach developed in human using interleukin (IL)-2-toxin (Denileukin diftitox; ref. 6) showed low efficacy possibly because of its limited specificity and the existence of toxicity. In the objective to increase T cell antitumor immunity, early clinical trial with the anti-CTLA4 mAb, recently approved in the treatment of melanoma, and anti-PD-1/PD-L1 showed remarkable long-lasting clinical benefit (7, 8) . However, contribution of Treg neutralization in the clinical efficacy of anti-CTLA4 mAb remains uncertain (9, 10) . Thus, there is an urgent need of alternative therapeutic strategies to selectively neutralize TA-Treg. A first step along this objective is the understanding of the immunosuppressive networks operating in the breast tumor microenvironment. We therefore undertook to characterize the mechanisms controlling TA-Treg enrichment within breast tumor.
We recently published that human TA-Treg recruitment in breast tumor from blood occurred through CCR4/CCL22 axis (2, 11) . Breast tumor TA-Treg are strongly activated, proliferate, and express high levels of the inducible costimulatory (ICOS) molecule (2) , suggesting the local recognition of a tumor-associated antigen, likely through presentation by a dendritic cell (DC) population. The presence of TA-plasmacytoid DC (pDC) within tumors has been correlated with poor prognosis in breast tumor (12) , ovarian carcinoma (13) , and melanoma (14) . Interestingly, pDC have been reported to strongly favor Treg proliferation in human (15) and rodent models (16) . Furthermore, TA-pDC are impaired in their major function of high IFNa secretion levels in response to TLR7/9-L in ovarian (13) and breast cancer (17) , and we recently showed that such functional defect strongly favors TA-pDC ability to induce TA-Treg proliferation and increases T-CD4 þ IL-10 secretion (17) , leading to the establishment of an immunosuppressive Tr1-like response. Identified in 1999 (18) , ICOS, a T cell costimulatory molecule of the CTLA4/PD1/CD28 family, plays a nonoverlapping function with CD28 (19) on CD4 þ T cells. In particular, ICOS is critical in the regulation of humoral response (20) through its role on T follicular helper cell activation as illustrated in ICOS KO mice (21) and deficient patients (22) . ICOS expression has also been linked with Treg maintenance in mice (23) and mucosal tolerance (24) . In human ICOS plays a predominant role in pDC/T-cell interaction (25) and participates in naive CD4 þ T cell polarization into IL-10-secreting Tr1-like cells (26) .
ICOS was also associated with Treg homeostasis in nonobese diabetic (NOD) mice (27) and with increased Treg proliferative capacity and immunosuppressive functions (28) . All these observations led us to decipher the contribution of ICOS in the establishment of tolerance through TA-Treg amplification in breast tumor mediated by TA-pDC. Using a new blocking mAb against ICOS (clone 314.8), we showed that ICOS blockade inhibited pDC-induced TA-Treg proliferation and reduced IL-10 secretion by memory TA-TCD4 þ without interfering with mDC-induced TA-TCD4 þ activation. Finally, we showed that the presence of ICOS þ cells within primary breast tumor correlated with poor patients' survival. Thus, supported by the clinical efficacy of anti-CTLA4 and anti-PD-1/PD-L1 (7, 8, 29) , a neutralizing anti-ICOS mAb would represent a potent therapeutic drug to neutralize Treg in breast cancers.
Materials and Methods
Tumor single cell suspensions, CD4 þ T cells and pDC isolation Primary breast tumor samples and blood in anticoagulant (CTAD)-coated tubes were obtained from non-pretreated patients diagnosed for primary breast carcinoma provided by the Centre L eon B erard (CLB) tissue bank after written informed consent in accordance with the Declaration of Helsinki. The study was reviewed and approved by the Institutional Review Board of CLB. Human tonsils were obtained anonymously according to the institutional regulations and healthy donor (HD) human blood was purchased anonymously from the EFS.
Isolation of T cells and DC from tumor and healthy donor tissues
Tumor and tonsil single cell suspensions were generated as previously described (2) . Healthy donor or patients' blood mononuclear cells were obtained by Ficoll density gradient. Viable HD-pDC (Lin
were fluorescence-activated cell sorting (FACS) sorted from tonsil samples as described previously (13 Allogeneic DC/T-cell cocultures and anti-CD3/anti-CD28-coated beads T cells activation pDC and mDC were preactivated for 24 hours in presence of IL-3 (20 ng/mL; Peprotech) AE granulocyte macrophage colonystimulating factor (GM-CSF; 10 ng/mL; Schering Plough) with R848 (5 mg/mL; Invivogen) in RPMI medium supplemented with antibiotics, L-glutamin (Life Technologies), and 10% fetal calf serum (PAA). Activated DC were washed before coculture with T cells.
Cocultures were conducted at a DC:T cells ratio (1:5) for 5 days with or without exogenous rhIL-2 (Pro-Immune) in presence of IL-3 (20 ng/mL) AE GM-CSF (10 ng/mL) in RPMI containing 5% AB human pooled serum (EFS 
IHC
Frozen breast tumor sections (5 mm) were subjected to sequential double IHC analyses with mAbs against BDCA-2 (10 mg/mL), FoxP3 (10 mg/mL), and cytokeratin (1/50) using ImmPRESS Anti-Mouse Ig peroxidase kit (Abcys), as previously described (2).
After antigenic retrieval by CC1 buffer pH8 (Ventana), breast tumor paraffin-embedded tissue microarray (TMA) were incubated for 30 minutes with Anti-ICOS mAb (1:50, Spring Biosciences), then revealed using Ultra View Kit and Hematoxylin-counterstained (Ventana Cytokines (IL-10, IFNg, and IL-2) secretions were quantified in supernatants by specific ELISA according to manufacturers' instructions (Bender MedSystems).
Statistical analysis
All statistical analyses were done using the Statistical SAS V9.2 package (Cay) 12.0 software. Correlations between clinicobiologic data and ICOS þ cell content in the lymphoid infiltrates were determined using a x 2 test or a Fisher exact test. Survival curves were plotted using the Kaplan-Meier method and compared using the Log-rank test. Fig. S1A ). Interestingly, the percentage of Ki67 þ cells was higher (P < 0.001) among To decipher the mechanisms controlling the strong proliferation of TA-Treg in vivo, we first compared the proliferative capacity of purified Treg and Tconv from healthy donor blood and breast tumor patients in response to costimulation using anti-CD3/anti-CD28-coated beads in the presence of high doses of rhIL-2 ( Fig. 2A) . Contrasting to the in vivo observations, TA-Tconv proliferated as well as healthy donor blood Tconv or Treg, whereas isolated TA-Treg did not proliferate, suggesting that other signals from the breast tumor microenvironment are involved in TA-Treg in vivo proliferation.
Results

CD4
Through IHC stainings conducted on breast tumor frozen sections, we observed S2B ) and a strongly reduced IL-2 concentration in culture supernatants, directly dependent on the Treg proportion ( Supplementary Fig. S2C ). Altogether, these results are consistent with the ability of pDC to sustain Treg immunosuppressive functions.
Collectively these data showed that in contrast to CD3/ CD28 costimulation, TLR7-L-activated HD-pDC induced and maintained TA-Treg enrichment among TA-TCD4 þ . Such enrichment resulted at least in part from a higher proliferation of FoxP3 hi TA-Treg, rising the hypothesis that another costimulatory signal different from CD28 required for TA-Treg expansion is delivered during pDC/TA-TCD4 þ interaction. Activated pDC are known to express high ICOS-L levels (25, 26) and we previously described a partly activated status of TApDC within breast tumor environment (17) . Consistently, TApDC expressed higher CD80 and CD40 levels than blood pDC and a similar upregulation was observed on TA-mDC. Contrasting to such activated phenotype, ICOS-L was undetectable on freshly isolated TA-pDC whereas healthy donor or patients' blood pDC expressed ICOS-L upon isolation and upregulated levels upon activation ( Fig. 3A and Supplementary Fig. S3A ).
ICOS-L may be downregulated on TA-pDC membrane after engagement with ICOS highly expressed by TA-Treg. In line with this, ICOS-L expression on TLR7-L activated HD-pDC was prevented in the presence of high numbers of allogeneicactivated blood HD-TCD4 þ and this blockade was reverted in presence of a neutralizing anti-ICOS mAb (Fig. 3B) . To confirm the relevance in breast tumor, ICOS-L expression was analyzed, on TA-pDC and TA-mDC, after 48 hours culture of whole tumor cell suspension in IL-3 favoring TA-pDC survival and the impact of blocking ICOS was assessed. Interestingly, TA-pDC highly expressed CD86 in all culture conditions ( Supplementary Fig. S3B ) but ICOS-L was detectable at high level on TA-pDC only after culture with neutralizing anti-ICOS mAb and not with anti-CD28 mAb (Fig. 3C) . As reported previously (26) , high expression of ICOS-L was restricted to HD-pDC as ICOS-L was only marginally detected on mDC from healthy donor blood or breast tumor (Fig. 3A) , even in the presence of TLR7-L ( Supplementary Fig. S3A ) or anti-ICOS mAb (Fig. 3C ) although they strongly expressed CD86 (Supplementary Fig. S3B ). Collectively, these observations strongly suggest that ICOS/ ICOS-L is involved in TA-Treg and TA-pDC interaction in breast tumor leading to the downregulation of ICOS-L expression on TA-pDC. moderately the proportion of proliferating HD-Tconv (78.1% and 52.2% in control and anti-ICOS mAb, respectively; Fig. 4C ). Interestingly, ICOS neutralization in HD-Treg/HD-pDC coculture decreased the proportion of FoxP3 hi Treg from 19 AE 2.4% to 3.3 AE 1% (6-fold, Fig. 4D ) although the proliferation of HDTconv was only moderately affected.
The efficacy of anti-ICOS mAb to reduce Treg proportion was evaluated on TA-TCD4 þ , even in the presence of exogenous rhIL-2. In accordance with results on HD-TCD4 þ , the FoxP3 hi subpopulation induced by HD-pDC decreased in the presence of anti-ICOS mAb (13.5 AE 2% vs. 4 AE 1% in control and anti-ICOS mAb, respectively; Fig. 5A and B) . In reverse experiments, purified IL-3AETLR7-L preactivated TA-pDC favored a strong Treg enrichment among HD-TCD4 þ (containing initially 1.7% of FoxP3 hi Treg) at day 5 (7.1-and 6.4-fold increase with IL-3 and IL-3þTLR7-L-preactivated TA-pDC, respectively). As expected, such Treg enrichment was strongly reduced by ICOS neutralization (57%-83% reduction in FoxP3 hi cells compared with control condition; Fig. 5C and D) . Taken together, these results showed the critical role of ICOS/ICOS-L interaction in TA-pDC-mediated TA-Treg amplification in breast tumor.
ICOS neutralization inhibits pDC-induced IL-10 secretion by T-CD4 þ
We evaluated IL-10 and IFNg production by HD-Tconv and HD-Treg cocultured with preactivated pDC. In HD-pDC/HDTconv coculture with exogenous rhIL-2, ICOS blockade (Fig. 6B,  right panel) . IFNg secretion was also significantly, but to a lesser extent, inhibited upon ICOS neutralization in all culture conditions (59%-63%). Consistent with the strong IL-10 secretion induced by pDC, we detected high IL-10 levels in 48-hourculture supernatants of breast tumor single cell suspensions ( Supplementary Fig. S5 ) in 7/13 tumors tested [median ¼ 646.8 pg/mL, range (3.2-6915) pg/ml] while IL-2, IL-17, and IFNg were never observed.
Finally, we investigated the impact of ICOS blockade on mDC, pDC, or mDCþpDC/T cell cocultures. In presence of exogenous rhIL-2 HD-TCD4 þ cocultured with HD-pDC produced more IL-10 but less IFNg than with HD-mDC (respectively, 596 AE 103 pg/mL and 181 AE 28 pg/mL for IL-10 and 279 AE 52 pg/mL and 641 AE 9 pg/mL for IFNg; Fig. 6C ). Culture of HD-TCD4 þ with mixed DC subsets resulted in lower IL-10 (232 AE 9 pg/mL) but higher IFNg secretion (574 AE 80 pg/mL) compared with [pDCþTCD4 þ ] cocultures. ICOS neutralization strongly reduced IL-10 levels (82% for pDC, 50% for mDC, and 62% for pDCþmDC) without significantly interfering with IFNg secretion (þ28% for pDC, À19% for mDC, and À24% for pDCþmDC) contrasting with observations done with cells from breast tumor origin (Fig. 6C) . In absence of exogenous rhIL-2, except the lower levels of IL-10 and IFNg, similar effects of ICOS neutralization were observed. Furthermore, ICOS blockade increased IL-2 concentration in coculture with HD-pDC (P ¼ 0.035, Fig. 6D ).
Overall these results showed that ICOS blockade leads to a strong inhibition of pDC-induced IL-10 secretion by HD-TCD4 þ that is accompanied by increased levels of IL-2, without significantly affecting IFNg production, in particular, in response to mDC. (P < 0.001), absence of ER expression (P ¼ 0.025) and Her2/neu overexpression (P ¼ 0.017) by tumor cells, triple negative status (P ¼ 0.02), and lymphatic emboles (P < 0.001; Supplementary  Table S1 ). Importantly, in univariate analysis the presence of ICOS þ cells in lymphoid-enriched areas was associated with an increased risk of relapse (progression-free survival, Log-rank P value ¼ 0.0285; Fig. 7D ) and death (overall survival, Log-rank P value ¼ 0.0465; Fig. 7E ). However, when introduced in a multivariate analysis together with other significant clinical and biologic parameters, high ICOS expression was no more significant.
Detection of ICOS
Discussion
In addition to our previous reports demonstrating that TA-Treg frequency within tumor lymphoid infiltrates correlates with poor prognosis in primary breast tumor (2, 30), we identify herein ICOS engagement as a major pathway contributing to their local accumulation through direct interaction with TA-pDC.
We confirm that TA-Treg within primary breast tumor express high ICOS and Ki67 levels in a specific manner compared with other TA-TCD3 þ subsets or blood Treg. Interestingly, TA-Tconv and TA-TCD8 þ contain a low minority of To date TA-Treg origin is not fully elucidated. pDC are known to favor immunosuppressive T-cell induction on both TCD4 þ (15, 41) and TCD8 þ (42) subsets and we cannot formally exclude the differentiation of Treg from naive TCD4 þ , as previously reported for both human and mouse pDC (41, 43, 44) . However, we recently showed (i) a specific recruitment of CCR4 þ Treg from the blood to breast tumor through the tumor cells CCL22 production (2, 11) , and (ii) that all of TA-TCD4 þ are of memory phenotype, consistent with a recruitment of TA-Treg from the periphery followed by their local expansion through ICOS/ICOS-L interaction with pDC in breast tumor environment.
In accordance with results in NOD type 1 diabetes murine model (27) subpopulation that do not secrete and/or consume high amounts of IL-2 in culture. This correlates with previous results (45) showing that T-cell responses under ICOS stimulation depend on exogenous rhIL-2.
Of most importance, IHC staining on 120 primary breast tumors with more than 10 years clinical follow-up allows to show that presence of high numbers of ICOS þ cells infiltrating primary breast tumors is associated with poor prognosis in univariate analysis but is no more significant when introduced in the multivariate analysis together with other significant clinical and biologic parameters. Collectively our results suggest that abrogation of ICOS/ ICOS-L interaction using neutralizing anti-ICOS mAb may reduce Treg expansion, IL-10 secretion, and IL-2 consumption by TA-TCD4 þ that can favor antitumor immunity through ICOS-independent TCD8 þ and TCD4 þ activation.
This role of ICOS in TA-Treg biology is supported by the fact that (i) ICOS þ Treg have a stronger suppressive function in melanoma (46) and murine models (27, 28) , and (ii) ICOS deletion in human (22) and mice (23) correlates to a decreased Treg proportion.
On the other hand ICOS could be expressed on activated T cells (47) and ICOS expression is upregulated on IFNg secreting T cells during anti-CTLA4 treatment in phase III trials in melanoma patients (for review 33). However, there is no evidence in these clinical trials that ICOS contributes to antitumor immunity and ICOS may simply represent a Tcell effector marker. This could suggest that treatment with neutralizing anti-ICOS mAb needs to be restricted to a short time period to abrogate Treg amplification without impacting on potential restoration of effector cells expressing ICOS.
The treatment by the anti-ICOS 314.8 mAb may be particularly relevant in neo-adjuvant settings combined to therapies inducing antitumor immunity by favoring tumor cell death such as therapies targeting tumor molecular alterations (Herceptin, lapatinib; ref. 48) or immunogenic chemotherapies (anthracyclins; ref. 49 ).
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